Boston Scien Cp Stock Price, News & Analysis

Boston Scientific Corporation (NYSE: BSX) has scheduled a conference call for October 26, 2022, at 8:00 a.m. EDT to discuss financial results and business highlights for Q3 2022, which ended on September 30. The call will be led by CEO Mike Mahoney and CFO Dan Brennan. A press release with the financial results will be issued prior to the call. Investors can access the live webcast and replay on the company’s investor relations website.

Boston Scientific Corporation (BSX) presented results from the PROTECTED TAVR trial at TCT 2022, evaluating the SENTINEL Cerebral Protection System. The trial aimed to assess the reduction of strokes in TAVR patients. While the primary endpoint was not met, a non-significant trend showed a 21% relative risk reduction in all strokes (2.3% with SENTINEL vs. 2.9% without). Notably, there was a significant 60% reduction in disabling strokes (0.5% with SENTINEL vs. 1.3% without, P=0.02). The study involved 3,000 patients across over 50 sites, emphasizing the SENTINEL device's potential benefits in stroke prevention.

Boston Scientific (NYSE: BSX) has received FDA approval to expand the labeling for its WATCHMAN FLX Left Atrial Appendage Closure Device. The update allows for a 45-day dual anti-platelet therapy (DAPT) option as an alternative to the existing oral anticoagulation (OAC) regimen for patients with non-valvular atrial fibrillation (NVAF). This change provides physicians with more treatment flexibility based on patient needs. Clinical data, including analyses of over 8,300 patients, supports the safety and efficacy of the DAPT regimen. The device demonstrated significant advantages in clinical trials, including higher rates of complete occlusion compared to competitors.

Boston Scientific Corporation (NYSE: BSX) will participate in two investor events in September 2022. On September 7, CEO Mike Mahoney and VP Lauren Tengler will engage in a fireside chat at the Wells Fargo Healthcare Conference at 3:10 p.m. EDT. On September 18, the company will host an investor event at the 34th Transcatheter Cardiovascular Therapeutics meeting from 9:00 a.m. to 10:00 a.m. EDT. Key executives will provide a business update. Webcasts of both events will be available online.

Boston Scientific Corporation (NYSE: BSX) announced the acquisition of Obsidio, Inc. on August 15, 2022. The acquisition incorporates Obsidio's Gel Embolic Material (GEM^™) technology, recently cleared by the FDA, into Boston Scientific's interventional oncology and embolization portfolio. GEM technology is designed for efficient embolization procedures, offering advantages over current embolics by providing immediate obstruction of blood flow. The transaction is expected to have an immaterial impact on Boston Scientific's earnings in 2022.

Nevro Corp. and Boston Scientific Corp. have resolved their intellectual property litigation through a settlement. This agreement allows Boston Scientific to operate with its current products utilizing features below 1,500 Hz while granting Nevro similar freedoms. Nevro will license paresthesia-free therapy technology to Boston Scientific, and vice versa. The settlement also includes a net payment of $85 million from Boston Scientific to Nevro, concluding all ongoing litigations between the two parties.

Boston Scientific generated $3.244 billion in net sales for Q2 2022, marking a 5.4% year-over-year increase. GAAP net income reached $246 million or $0.17 per share, compared to $172 million or $0.12 per share in 2021. Adjusted EPS improved to $0.44 from $0.40. Segments such as MedSurg and Cardiovascular reported solid growth, with emerging markets soaring 18.9%. However, U.S. growth was strong at 7.4%, while EMEA faced a slight decline of (0.3%). The company expects 6.5% to 7.5% growth for the full year and continued operational success.

Boston Scientific will host a conference call on July 27, 2022, at 8:00 a.m. EDT to discuss its second-quarter financial results for the period ending June 30, 2022. The call will feature CEO Mike Mahoney and CFO Dan Brennan. A news release detailing the financial results will be issued prior to the call. Investors can access the live webcast and subsequent replay on the company’s investor relations website.

Boston Scientific Corporation (NYSE: BSX) has entered into a definitive agreement to acquire a 64% stake in M.I.Tech Co., Ltd., a Korean medical device manufacturer, for approximately $230 million. M.I.Tech is known for its HANAROSTENT™ technology, which features self-expanding metal stents used in various minimally invasive medical procedures. This acquisition is expected to enhance Boston Scientific's stent portfolio and expand M.I.Tech's international presence. The transaction is scheduled to close in the second half of 2022, with an immaterial impact on earnings projected for that year.